Category Archives: Immunology

Cohort profile: Prematurity Immunology in Mothers living with HIV and their infants Study (PIMS) – DocWire News

This article was originally published here

BMJ Open. 2021 Sep 30;11(9):e047133. doi: 10.1136/bmjopen-2020-047133.

ABSTRACT

PURPOSE: Prematurity Immunology in Mothers living with HIV and their infants Study (PIMS) is a prospective cohort study in South Africa investigating the association between antiretroviral therapy (ART) use, preterm delivery (PTD) and small-for-gestational age (SGA) live births. PIMS main hypotheses are that ART initiation in pregnancy and ART-induced hypertension are associated with PTD and SGA respectively and that reconstitution of cellular immune responses in women on ART from before pregnancy results in increases in PTD of GA infants.

PARTICIPANTS: Pregnant women (n=3972) aged 18 years regardless of HIV status recruited from 2015 to 2016 into the overall PIMS cohort (2517 HIV-negative, 1455 living with HIV). A nested cohort contained 551 women living with HIV who were 24 weeks GA on ultrasound: 261 initiated ART before pregnancy, 290 initiated during the pregnancy.

FINDINGS TO DATE: Women in the overall cohort were followed antenatally through to delivery using routine clinical records; further women in the nested cohort were actively followed up until 12 months post partum, with data collected on maternal health (HIV care and ART use, clinical care and intercurrent clinical history). Other procedures conducted on the nested cohort included physical examinations (anthropometry, blood pressure measurement), assessment of fetal growth (ultrasound), maternal and infant phlebotomy for storage of plasma, RNA and peripheral blood mononuclear cells, collection of delivery specimens (placenta and cord blood) and infant 12-month developmental assessment. Preliminary findings have contributed to our understanding of risk factors for adverse birth outcomes, and the relationship between pregnancy immunology, HIV/ART and adverse birth outcomes.

FUTURE PLANS: Using specimens collected from study participants living with HIV throughout pregnancy and first year of life, the PIMS provides a valuable platform for answering a variety of research questions focused on temporal changes of immunology markers in women whose immune status is altered by HIV infection, and how ART initiated during the pregnancy affects immune responses. The relationship between these immunological changes with adverse birth outcomes as well as possible longer-term impact of exposure to ART in fetal and early life will be explored. Additionally, further active and passive follow-up of mothers and their infants is planned at school-going age and beyond to chart growth, morbidity and development, as well as changes in family circumstances.

PMID:34593488 | DOI:10.1136/bmjopen-2020-047133

Go here to read the rest:
Cohort profile: Prematurity Immunology in Mothers living with HIV and their infants Study (PIMS) - DocWire News

Global Immunology Drug Market 2021 Industry Insights and Major Players are Abbott Laboratories, Active Biotech, Eli Lilly and Company, Autoimmune…

Comprehensive Global Immunology Drug Market from 2021 to 2027 analysis with precise projections and predictions, as well as full research solutions for strategic decision-making, are provided by Market Research Place studies. It also has separate chapters that include the regional studies to get a picture of the markets with future opportunities followed by the estimated yearly growth during the survey period from 2021 to 2027.

The report investigates the market by examining market dynamics, market trends, current trends, issues, challenges, competition analysis, and the firms involved. The study also goes into great detail on supply and demand assessments, as well as the participation of major industry players and market share growth statistics. All of the income margins, pricing, revenue proportions, and gross margins are determined in part.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketresearchplace.com/report-detail/216577/request-sample

It examines the market segments in the Immunology Drug market in depth:

The study takes into account a diverse variety of manufacturers, with business profiles of included

It provides granular analysis of the market segments of the Immunology Drug market:

The evaluation covers the major geographical areas that the industry operates in, including

ACCESS FULL REPORT: https://www.marketresearchplace.com/report/global-immunology-drug-market-research-report-2021-2027-216577.html

Main Points of the Report

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketresearchplace.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketresearchplace.com

Read the rest here:
Global Immunology Drug Market 2021 Industry Insights and Major Players are Abbott Laboratories, Active Biotech, Eli Lilly and Company, Autoimmune...

‘Last throw of the dice’ for Covid-19, claims Professor Luke O’Neill – Dublin Live

A leading immunology expert has given hope that Covid-19 may finally be on its "last throw of the dice".

The Delta variant completely changed how the public lives with Covid-19 given its higher transmissibility compared to previous strains of the disease.

But Professor Luke O'Neill of Trinity College told Today with Claire Byrne this morning that Delta "may be as bad as it gets" with vaccines holding firm against it.

"The vaccine is holding firmly against Delta is the message," he said.

A new study shows protection from the Pfizer vaccination remains at 90% six months after the second dose is administered.

However, Professor O'Neill adopted a more cautious tone when it came to giving booster shots to the wider population.

Professor O'Neill said: "It may change when it gets to nine months out or 12 months, then that might be slightly different."

He added if there's evidence of increased risk in six months time "then you may start giving a booster - it may well become a three-shot vaccine finally".

To get the latest breaking news straight to your inbox, sign up for our free newsletter

Read more:
'Last throw of the dice' for Covid-19, claims Professor Luke O'Neill - Dublin Live

U of M research: vaccine offers greater protections for those who’ve already had COVID – MinnPost

The Star Tribunes Jeremy Olson writes: New University of Minnesota research is contesting a key argument against COVID-19 vaccination that people with prior coronavirus infections dont need further immunization to protect themselves. Comparing blood samples following COVID-19 vaccinations in 48 participants, the U researchers found that everyone gained key memory B cells capable of producing antibodies that fight off the coronavirus, but people with previous infections gained five times more of those cells. And in the world of immunology, more is better, said Marc Jenkins, a co-author and director of the Center for Immunology at the U Medical School.

WCCO-TV reports: Violence Free Minnesota released its 2020 homicide report on Friday, which analyzes relationship abuse in the state. In all, the report says that at least 30 people were killed due to intimate partner violence in 2020, and all but one of the victims identified as a woman. Of the 30 victims, 21 were killed by a current or former intimate partner, and nine victims were friends or family members attempting to intervene. Three of the victims were children.

For MPR, Mat Sepic writes: The lawyers prosecuting Kimberly Potter, the former police officer who killed Daunte Wright, are planning to introduce evidence showing that Potter was trained in the proper use of a Taser. As Potter, 49, and another Brooklyn Center officer tried to arrest Wright on a firearms warrant during a traffic stop April 11, he broke free and got back in his car. Potter is heard on video shouting Taser but instead pulls her handgun and shoots Wright in the chest. Potter is charged with first and second-degree manslaughter.

At FOX 9, Howard Thompson reports: A man is in custody after a police chase turned into a standoff with shots fired in Duluth, Minnesota on Friday. In tweets Friday evening, police say the suspect, who officers say was wanted following an attempted bank robbery and police chase, surrendered at about 8:30 p.m., hours after the incident began. According to police, the incident started at about 12:30 p.m. with a pursuit through the city and surrounding areas.

Article continues after advertisement

For MPR, Jon Collins writes: A pilot program launching Monday is aimed at freeing up Minneapolis police by using civilian city employees to enforce parking violations overnight. Parking control officers have traditionally enforced parking regulations during daylight hours and then handed duties off to the Minneapolis police for the night. Saray Garnett-Hochuli, interim director for regulatory services, said complaints about parking violations during these hours often went unaddressed because they were a low priority for police.

In the Pioneer Press, Betsy Helfand writes: A season that began with playoff aspirations will officially end with a fifth-place finish for the Twins, their first time winding up in the American League Central cellar since 2016, when they finished with the worst record in the majors. With an 11-6 loss to Kansas City on Friday night at Kauffman Stadium, the Twins (71-89) are three games behind the Royals (74-86) with two to play, locking them into fifth place in 2021 after winning division titles in each of the past two seasons.

Stephen Groves writes for the AP: South Dakota Gov. Kristi Noem on Friday defended her administrations handling of her daughters application for a real estate appraiser license, attempting to brush aside questions about a meeting she held last year that included her daughter, Kassidy Peters, and the state employee who was overseeing her application. I never once asked for special treatment for Kassidy, the Republican governor said in video posted on YouTube days after The Associated Press first reported on the meeting. The meeting happened after the Department of Labor and Regulation moved to deny Peters the license. Four months later, in November 2020, Peters received her certification as a residential appraiser, according to the department.

Here is the original post:
U of M research: vaccine offers greater protections for those who've already had COVID - MinnPost

Opinion: In reponse to Robert Wise – Northside Sun

In all my columns concerning this pandemic, I never mentioned attorney Robert Wise in any way, but he has chosen not only to attempt to insult me but even intruded on the border of slander by several not-so clever ploys. First, he searched the discredited attack professional groups who make a living attacking anyone who challenges the orthodoxy. I recognized the MO immediatelythey all use the same worn-out material. While not actually saying so, it might be construed from the way he presented it that I lost my medical license when in truth, I retired from my neurosurgical practice in 2007. When one retires it is customary to also retire ones medical license. Not mandatory, but if you never plan to return to clinical practice why continue to pay the fees each year? I am almost 76 years oldwe do retire.

There is an old saying that If you cannot answer a mans arguments, all is not lostyou can still call him vile names. Many of those attacking those of us who believe in informed consent, that is, the right of the public to know all the facts concerning a proposed treatment, think like despots in totalitarian countries, assuming that only official or state controlled information should have access to the public square. One can always tell when a groups so-called information is tainted and cannot be openly defended. The controllers of information immediately use the courts or bureaucracies to control the debate, and they resort to personal attacks. We call that dirty pool or attack journalism.

My opinion, reading Wises latest nonsense being sold as reasoned argument, is that it is a cry of desperation and frustration at being intellectually unarmed. As for my credentials, I am the associate editor-in-chief of the neuroinflammatory section of the international journal Surgical Neurology International, one of the most read international neurosurgical journal in the world. In this position, I peer review submitted articles from experts on subjects dealing with immunology, neuroinflammation and infectious diseases affecting the brain and spinal cord.

I have around 60 articles published in a variety of scientific publications, a number dealing with immunology and the effects of vaccines on the central nervous system. My articles have been cited by other scientific journal articles over 1000 times. I am cited in a number of prestigious scientific papers as well as having a textbook chapter on immunoexcitotoxicity as a major pathophysiological mechanism for chronic traumatic encephalopathy (Biomarkers for Traumatic Brain Injuries, 2012, Dambinova SA et al eds). I have published articles on the pathophysiology of vaccine damage to the developing brain, articles that are widely cited in the scientific literature. I work with some of the top experts in immunology, vaccine complications and the effects of these vaccines on the nervous system. In addition, I have a two-part article published as an extensive primer for neurologists and neurosurgeons on immunology, both acquired and innate, which was reviewed by one of the top experts in immunology at UCLA Medical Center.

I have written six books on medical subjects and contributed chapters in four textbooks as well. What I find strange is that our illustrious attorney has, as far as I know, published nothing in the scientific literature on any of these subjects. All he can seem to do is tell emotional just-so stories and quote medical bureaucracies, such as the CDC and WHO, that are making millions off these and other vaccines. Both these bureaucracies are known to be corrupt to the core. The CDC has never treated a single patient for a covid-19 infection, yet they designed the protocol for most hospitals, that is generally rigidly enforced. Their protocol, in my opinion and others, was and continues to be responsible for a large percentage of the covid deaths in these hospitals.

The CDC also established the insane idea that infected people should stay at home, use no early treatments, until they were so sick, they require hospital or even ICU treatment. To compound this, they told people they should just take Tylenol and drink lots of liquids. Tylenol is a very dangerous drug and is responsible for a high percentage of serious complications seen in our hospitals. Each year we have over 700 deaths from Tylenol complications and during that same period there were only 2 deaths from Ivermectin. Every country that has initiated, as state policy, the use of Ivermectin has seen a dramatic and rapid drop in hospitalization and deaths. Some 27 randomized clinical studies from all over the world confirm that Ivermectin is very safe and dramatically reduces the death rate associated with this infection. Other early treatments, according to carefully controlled studies, have reduce death rates by as much as 80%, which if initiated by all states would have saved tens of thousands of lives. Instead, medical societies threaten our doctors with a loss of their license should they even speak anything but the incessant propaganda by the CDC and other medical bureaucracies. It is this massive control of medical information that is responsible, in my opinion and others, for the mass death associated with this virus.

Keep in mind that we would not be suffering from this never-ending pandemic had not Dr. Fauci, along with his cohorts, not supplied the Chinese communist bioweapons lab in Wuhan, China with millions of dollars in aid, as well as supplying critical information on viral gain-of-function from Dr. Ralph Barik in Chapel Hill North, Carolina.

Our Wise loves to quote stories of individuals who have died because they were unvaccinated, but he quotes none of the thousands of stories of those whose lives have been destroyed or ended by the vaccines, including the loss of a significant number of babies of pregnant women. In fact, according to an analysis of the data from the VAERS government reporting system, 4,524 cases of vaccine-linked myocarditis and pericarditis were reported from 9/3/2021. Of these, 385 occurred in children age 12 to 17 years of age. The figure continues to rise rapidly. Incredibly, 86% of healthy vaccinated boys required hospitalization. Those childrens lives have been ruined forever. They may never play sports, hike strenuous trails, or look forward to any semblance of a normal life, rather they can look forward to a life of cardiac incapacity of a progressive nature. All this over a vaccine that has been shown not to protect, was poorly tested before being released and used among an age group that was experiencing virtually no risk from this virus.

In my opinion and others, these children were the victims of the fear mongering and lying propaganda by the government agencies, medical associations, and the pharmaceutical-controlled media. As far as the so-called covid cases, there is no adequate testing to determine if a person has a clinical infection since the PCR test has been discontinued because it could not distinguish between the influenza virus and Covid-19. As we have seen all along, these so-called authorities are counting everything as being a covid hospital admission and/or death. As for the unvaccinated being the primary source of the viral transmission, we have learned that these authorities have a very interesting definition of being unvaccinatedeven a person who has had both doses of the vaccine, if they are admitted or die less than 14 days from the second dose they are labeledunvaccinated. This deception is used by all these vaccine promoting agencies.

I agree with a number of experts in this field, that it is the vaccinated that are primarily spreading this new virus variant, not the unvaccinated. Vaccinated parents are exposing their children in their home for very long periods. Fauci even admitted that the viral concentration in the nasopharynx of the vaccinated was very high and could be transmitted. Now we have most medical personnel acting as viral carriers and transmitters to their patients as they have been forced by hospitals and medical centers to be vaccinated.

Russell L. Blaylock, M.D.

See the original post here:
Opinion: In reponse to Robert Wise - Northside Sun

AbbVie to Host Third-Quarter 2021 Earnings Conference Call – WITN

Published: Oct. 5, 2021 at 8:00 AM EDT|Updated: 7 hours ago

NORTH CHICAGO, Ill., Oct. 5, 2021 /PRNewswire/ --AbbVie (NYSE: ABBV) will announce its third-quarter 2021 financial results on Friday, October 29, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us atwww.abbvie.com. Follow @abbvieon Twitter, Facebook, Instagram, YouTubeand LinkedIn.

View original content:

SOURCE AbbVie

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

Go here to read the rest:
AbbVie to Host Third-Quarter 2021 Earnings Conference Call - WITN

MCB Assistant Professor Cluster Hire-Neuroimmunology job with Montana State University | 388051 – The Chronicle of Higher Education

Three Faculty Positions in the Department ofMicrobiology & Cell Biology at Montana StateUniversity

This is where research and discovery happen. Located in theheart of the Rocky Mountains, Bozeman, Montana offers a healthylifestyle and a world class research university that facilitatesinnovation and scholarship. The Department of Microbiology &Cell Biology at Montana State University (MSU) invites applicationsfor three tenure track faculty positions in the field ofNeuroimmunology. This cluster hire aims to attract a diverse cohortof exceptional individuals that will establish nationallyrecognized, and externally funded research programs that useinnovative new methods to interrogate dynamic interactions at theinterface of Neurology and Immunology. Areas of interest include,but are not limited to, fundamental and applied biology,immunology, neurology, pathology, psychiatry, parasitology, aging,structural biology, and virology. Successful applicants willintegrate their research programs with undergraduate and graduatestudent instruction and participate in professional serviceactivities. We are particularly interested in individuals whosework complements and strengthens the research interestsofMSUfaculty, including those focused on neurology,developmental biology, immunology, microbial physiology andecology, molecular evolution, virology, biomedical microbiology,environmental health, structural biology, and host-pathogeninteractions. The Department of Microbiology & Cell Biologyoffers a dynamic research and teaching environment withstate-of-the-art facilities for infectious disease (e.g., BSL3),flow cytometry, light and cryo-electron microscopy, histology, andsmall and large animal research. The University supportscomprehensive cores in metabolomics, proteomics, imaging,structural biology, and genomics/bioinformatics. This position issupported by a competitive institutional salary, a generousstart-up package, and state-of-the-art research facilities. The jobdescription and application materials are available online(https://jobs.montana.edu/postings/25947).

Screening of applications will begin on October 15th, 2021 andscreening will continue until an adequate applicant pool has beenestablished. Montana State University values diverse perspectivesand is committed to continually supporting, promoting and buildingan inclusive and culturally diverse campusenvironment.MSUrecognizes the importance of work-lifeintegration and strives to be responsive to the needs of dualcareer couples. Equal Opportunity Employer, Veterans/Disabled

Please contact Kelley Kane (kelleykane@montana.edu) for moreinformation.

Read the rest here:
MCB Assistant Professor Cluster Hire-Neuroimmunology job with Montana State University | 388051 - The Chronicle of Higher Education

VBI Vaccines to Participate in Upcoming Investor Conferences – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that members of the management team will participate in analyst-led fireside chats at the following upcoming investor conferences:

Guggenheim 2nd Annual Vaccines & Infectious Disease ConferenceDiscussion to be held with Evan Wang Equity Research Senior Associate

H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) ConferenceDiscussion to be held with Patrick Trucchio Managing Director, Senior Healthcare Analyst

Live webcasts of the presentations will also be available on the Investors page of VBIs website at: https://www.vbivaccines.com/investors/events-and-presentations/. A replay of each webcast will be archived on the Companys website following the presentation.

About VBI Vaccines Inc.

VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (VLPs), including a proprietary enveloped VLP (eVLP) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, COVID-19 and coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

Cautionary Statement on Forward-looking Information

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, forward-looking statements). The Company cautions that such statements involve risks and uncertainties that may materially affect the Companys results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the ongoing COVID-19 pandemic on our clinical studies, manufacturing, business plan, and the global economy; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Companys ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Companys products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Companys filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 2, 2021, and filed with the Canadian security authorities at sedar.com on March 2, 2021, as may be supplemented or amended by the Companys Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.

Excerpt from:
VBI Vaccines to Participate in Upcoming Investor Conferences - Business Wire

Fate Therapeutics Announces Presentations at the Society – GlobeNewswire

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that one oral and four poster presentations for the Companys induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) being held November 10-14, 2021.

The oral presentation will highlight preclinical data for FT536, the Companys off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate that uniquely targets the 3 domain of the MHC class I related proteins A (MICA) and B (MICB). In a recent publication in Cancer Immunology Research (DOI: 10.1158/2326-6066.CIR-19-0483), Kai W. Wucherpfennig, M.D., Ph.D., Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and co-leader of the Cancer Immunology Program at Dana-Farber / Harvard Cancer Center, demonstrated that cancers with loss of MHC Class I expression can be effectively targeted with MICA/B 3 domain-specific antibodies to restore NK cell-mediated immunity against solid tumors. The FT536 program is supported by an exclusive license from the Dana-Farber Cancer Institute to intellectual property covering novel antibody fragments binding MICA/B for iPSC-derived cellular therapeutics. The Company expects to submit an Investigational New Drug (IND) application for FT536 in the fourth quarter of 2021 for the treatment of advanced solid tumors, including in combination with monoclonal antibody therapy.

Poster presentations at SITC will include preclinical data on new functional elements that the Company is evaluating for incorporation into its iPSC-derived cell product candidates for solid tumors. These synthetic features include engineered chemokine receptors, which the Company has demonstrated can enhance the trafficking and homing of iPSC-derived CAR T cells to tumors, and synthetic TGF re-direct receptors, which the Company has shown can exploit immuno-suppressive cytokines found in the tumor microenvironment to potentiate iPSC-derived CAR T cells and improve anti-tumor activity.

Oral Presentation

Poster Presentation

About MICA and MICB ProteinsThe major histocompatibility complex (MHC) class I related proteins A (MICA) and B (MICB) are induced by cellular stress, damage or transformation, and the expression of MICA and MICB proteins has been reported for many tumor types. Cytotoxic lymphocytes, such as NK cells and CD8+ T cells, can detect and bind the membrane-distal 1 and 2 domains of MICA/B, activating a potent cytotoxic response. However, cancer cells frequently evade immune cell recognition by proteolytic shedding of the 1 and 2 domains of MICA/B. The clinical importance of proteolytic shedding is reflected in the association of high serum concentrations of shed MICA/B with disease progression in many solid tumors. Several recent publications have shown that therapeutic antibodies targeting the membrane-proximal 3 domain strongly inhibited MICA/B shedding, resulting in a substantial increase in the cell surface density of MICA/B and restoration of NK cell-mediated tumor immunity (DOI:10.1126/science.aao0505). Therapeutic approaches aimed at targeting the 3 domain of MICA/B therefore represent a potentially promising novel strategy to overcome this prominent evasion mechanism as a means of restoring anti-tumor immunity.

About Fate Therapeutics iPSC Product PlatformThe Companys proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Companys first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Companys platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.

About Fate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the Companys clinical studies and preclinical research and development programs, its ongoing and planned clinical studies, and the safety and therapeutic potential of the Companys product candidates. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Companys product candidates may not demonstrate the requisite safety or efficacy to achieve regulatory approval or to warrant further development, the risk that results observed in prior studies of the Companys product candidates, including preclinical studies and clinical trials of any of its product candidates, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the manufacturing of the Companys product candidates or in the initiation of, or enrollment of patients in, any clinical studies, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, the amount and type of data to be generated, or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Companys ongoing and planned clinical trials, difficulties in manufacturing or supplying the Companys product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Companys actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Companys periodic filings with the Securities and Exchange Commission, including but not limited to the Companys most recently filed periodic report, and from time to time in the Companys press releases and other investor communications.Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact:Christina TartagliaStern Investor Relations, Inc.212.362.1200christina@sternir.com

Go here to see the original:
Fate Therapeutics Announces Presentations at the Society - GlobeNewswire

Lilly Selects ZS to Enhance Customer Engagement and Field Sales Effectiveness – Business Wire

EVANSTON, Ill.--(BUSINESS WIRE)--Global professional services firm ZS today announced that Eli Lilly and Co. is implementing ZAIDYN Field Insights. Lilly chose the offering to help accelerate its commercial digital transformation, enhance customer engagement and to better anticipate customer needs in an evolving healthcare ecosystem.

ZAIDYNs dynamic targeting solution helps life sciences field teams better listen, adapt and respond to changing customer needs. The solution meets these needs by embedding ZS artificial intelligence-enabled dynamic targeting and field suggestions directly into the tools where field teams manage their day-to-day activities.

Partnering with ZS allows us to equip our sales professionals with appropriate insights to anticipate our customers needs and deliver meaningful solutions in a timely and personalized way, said Patrik Jonsson, senior vice president and president of Lilly Immunology and Lilly USA, and chief customer officer. Adopting an agile approach that allows us to meet healthcare providers where they are with the right information will help us take our customer engagement and satisfaction to the next level.

ZS is the first in the industry to offer dynamic targeting capabilities at this scale with this level of analytical sophistication, and to deliver these capabilities directly through the clients existing customer engagement system. ZS clients already have begun to realize the benefits of using ZAIDYN Field Insights, including increased adoption of insights, identification of new healthcare providers and considerable time savings for the field team.

Sales teams can now better listen to, anticipate and respond to customer needs in the right way, at the right time, with the right message and through the right channel, said Maria Kliatchko, principal and lead, customer engagement products at ZS. They can nimbly adapt their targeting approach to changing market conditions and healthcare provider and patient needs.

About ZS

ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. We leverage our deep industry expertise, leading-edge analytics, technology and strategy to create solutions that work in the real world. With more than 35 years of experience and 10,000-plus ZSers in more than 25 offices worldwide, we are passionately committed to helping companies and their customers thrive. To learn more, visit http://www.zs.com or follow us on Twitter and LinkedIn.

Here is the original post:
Lilly Selects ZS to Enhance Customer Engagement and Field Sales Effectiveness - Business Wire